跳至主要内容
临床试验/ISRCTN38477744
ISRCTN38477744已完成不适用

A double-blind placebo-controlled randomised trial of oral sodium clodronate for metastatic prostate adenocarcinoma

Medical Research Council (MRC) (UK)0 个研究点目标入组 311 人开始时间: 2000年4月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
311

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Proven histological diagnosis of prostate cancer or Prostate-Specific Antigen (PSA) more than 100 mg/l
  • 2. Metastatic bone disease demonstrated on bone scan or skeletal radiographs (Stage M1b)
  • 3. Patients commencing or clinically responding to initial hormone treatment with orchidectomy, Luteinising Hormone Releasing Hormone (LHRH) analogues, cyproterone acetate, flutamide or complete androgen blockade but with no previous hormone treatment
  • 4. Normocalcaemic (serum calcium within the normal range of the centre)
  • 5. WHO performance status of 0, 1 or 2
  • 6. No concomitant or previous use of other bisphosphonates
  • 7. Serum creatinine less than twice upper limit of normal range of centre
  • 8. No administration of any investigational drug within 12 months

排除标准

  • Does not meet inclusion criteria

研究者

发起方
Medical Research Council (MRC) (UK)

相似试验